-
公开(公告)号：US20170298130A1
公开(公告)日：2017-10-19
申请号：US15325865
申请日：2015-07-17
Applicant: NOVO NORDISK A/S
Inventor： Anette Henriksen , Kristian Kjærgaard , Vibeke Westphal Stennicke , Charlotte Wiberg
IPC: C07K16/28
CPC classification number: C07K16/2803 , C07K2299/00 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
Abstract: Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
-
公开(公告)号：US20130309239A1
公开(公告)日：2013-11-21
申请号：US13954318
申请日：2013-07-30
Applicant: Novo Nordisk A/S
Inventor： Vibeke Westphal Stennicke , Christine Brender Read , Susanne Nedergaard Grell , Charlotte Wiberg , Rune Salbo , Anette Henriksen , Soeren Padkjaer
IPC: C07K16/28
CPC classification number: C07K16/2803 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/75 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
-
公开(公告)号：US10906965B2
公开(公告)日：2021-02-02
申请号：US16171131
申请日：2018-10-25
Applicant: Novo Nordisk A/S
Inventor： Vibeke Westphal Stennicke , Christine Brender Read , Joseph Leon Kuijper , Xiaoting Tang , Mark Heipel , Siv Annegrethe Hjorth
IPC: A61K39/395 , C07K16/18
Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
-
公开(公告)号：US20150018528A1
公开(公告)日：2015-01-15
申请号：US14376968
申请日：2012-11-30
Applicant: Novo Nordisk A/S
Inventor： Vibeke Westphal Stennicke , Christine Brender Read , Joe Kuijper , Xiaoting Tang , Mark Heipel , Siv Annegrethe Hjorth
IPC: C07K16/18
CPC classification number: C07K16/18 , C07K2317/565 , C07K2317/76
Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
Abstract translation: 本文公开了一种鉴定能够改变TREM-1配体功能的TREM-1的配体和抗体或其片段的方法。 可以使用该方法鉴定和选择减少或阻断TREM-1激活的抗体。 结合TREM-1的配体并降低TREM-1活性的抗体可能适合用作药物。
-
5.发明申请ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) 有权在MYELOID细胞-1（TREM-1）上表达的结合和阻断触发受体的抗体公开(公告)号：US20130211050A1
公开(公告)日：2013-08-15
申请号：US13690748
申请日：2012-11-30
Applicant: NOVO NORDISK A/S
Inventor： Vibeke Westphal Stennicke , Christine Brender Read , Susanne Nedergaard Grell , Charlotte Wiberg , Rune Salbo , Anette Henriksen , Soeren Padkjaer
IPC: C07K16/28
CPC classification number: C07K16/28 , A61K2039/505 , C07K16/2803 , C07K16/2896 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/74 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
Abstract translation: 本发明涉及能够特异性结合TREM-1并防止TREM-1的活化的抗体，TREM-1是在单核细胞，巨噬细胞和嗜中性粒细胞上表达的蛋白质。 这种抗体可用于治疗具有炎性疾病的个体，例如类风湿性关节炎和炎症性肠病。
-
Patent Agency Ranking
公开(公告)号：US10189904B2
公开(公告)日：2019-01-29
申请号：US15372600
申请日：2016-12-08
Applicant: Novo Nordisk A/S
Inventor： Vibeke Westphal Stennicke , Christine Brender Read , Susanne Nedergaard Grell , Charlotte Wiberg , Rune Salbo , Anette Henriksen , Soeren Padkjaer
IPC: A61K39/395 , C07K16/00 , C07K16/18 , C07K16/28 , A61K39/00
Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
-
7.发明授权Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) 有权在骨髓细胞-1（TREM-1）上表达的结合和阻断触发受体的抗体公开(公告)号：US09000127B2
公开(公告)日：2015-04-07
申请号：US13690748
申请日：2012-11-30
Applicant: Novo Nordisk A/S
Inventor： Vibeke Westphal Stennicke , Christine Brender Read , Susanne Nedergaard Grell , Charlotte Wiberg , Rune Salbo , Anette Henriksen , Soeren Padkjaer
IPC: A61K39/395 , C07K16/00 , C07K16/18 , C07K16/28 , A61K39/00
CPC classification number: C07K16/28 , A61K2039/505 , C07K16/2803 , C07K16/2896 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/74 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
Abstract translation: 本发明涉及能够特异性结合TREM-1并防止TREM-1的活化的抗体，TREM-1是在单核细胞，巨噬细胞和嗜中性粒细胞上表达的蛋白质。 这种抗体可用于治疗具有炎性疾病的个体，例如类风湿性关节炎和炎症性肠病。
-
公开(公告)号：US10179814B2
公开(公告)日：2019-01-15
申请号：US15325865
申请日：2015-07-17
Applicant: NOVO NORDISK A/S
Inventor： Anette Henriksen , Kristian Kjærgaard , Vibeke Westphal Stennicke , Charlotte Wiberg
IPC: C07K16/28
Abstract: Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
-
公开(公告)号：US10150809B2
公开(公告)日：2018-12-11
申请号：US15483390
申请日：2017-04-10
Applicant: Novo Nordisk A/S
Inventor： Vibeke Westphal Stennicke , Christine Brender Read , Joseph Leon Kuijper , Xiaoting Tang , Mark Heipel , Siv Annegrethe Hjorth
IPC: A61K39/395 , C07K16/00 , C07K16/18 , C07K16/28
Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
-
公开(公告)号：US09663568B2
公开(公告)日：2017-05-30
申请号：US14376968
申请日：2012-11-30
Applicant: Novo Nordisk A/S
Inventor： Vibeke Westphal Stennicke , Christine Brender Read , Joseph Leon Kuijper , Xiaoting Tang , Mark Heipel , Siv Annegrethe Hjorth
IPC: A61K39/395 , C07K16/00 , C07K16/18 , C07K16/28
CPC classification number: C07K16/18 , C07K2317/565 , C07K2317/76
Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.023 seconds)
